We are focused on discovering and developing medicines that improve the lives of people by addressing conditions with high unmet medical need.
Our growing pipeline of programs is deeply rooted in science, powered by our technology, and driven by people who are here to make a difference.
IND = Investigational New Drug application in the United States. Applications may be submitted to other jurisdictions, including Clinical Trial Applications (CTA) in Canada.
An engine to bring medicines from target to the clinic.
By integrating computation, engineering and biology, we aim to repeatedly develop differentiated antibody-based therapies from target to the clinic.
We are a team of scientists, engineers, creatives, and business professionals who believe that advancing science enhances lives.
And it all starts with our team. We’ve built a place where people feel they are part of something bigger than themselves. A place that exists to push the limits of science and technology, and aims to bring better therapies to patients.
When I saw a Canadian company tackling such globally impactful problems, I immediately wanted to join the team. Everyone I work with is engaged, interested, and passionate about the work we are doing!
Jessica Patterson, Head of Target Assessment
Our family relocated to Vancouver from Boston — it’s a great place to raise our kids. We’re big hikers, bikers, and skiers, and take every chance we get to drive 25 min to the mountains and go on an adventure!
Allie Goodman, Associate Scientific Director
I wanted to keep doing work that could directly impact patient health. AbCellera allows me to do that, all while working with an incredibly collaborative team who do what it takes to get the job done together.
Grace Leung, Associate Scientific Director
AbCellera’s commitment to people, teams, and relationships is what drew me towards the company. I’m surrounded by brilliant, kind, and down-to-earth people every day, and I’m excited to contribute to this team.
Tiffany Mintah, Learning and Development Program Manager
Meet with our team to discuss how we can expand the reach of antibody therapies.
AbCellera will be presenting a poster: Strategies for tailoring T-cell engager design for solid tumor indications at AET US 2024
AbCellera will be presenting a poster: Discovery of diverse GPCR-targeted antibodies using integrated technologies at PEGS 2024.
AbCellera will be presenting a poster: Designing T-cell engagers with high potency and low cytokine release at Festival of Biologics Europe 2024.
AbCellera will be presenting a poster: Discovery of diverse GPCR-targeted antibodies using integrated technologies at Discovery on Target 2024.
AbCellera will be presenting a poster: Target-dependent considerations for the design of bispecific T-cell engagers at Immuno-Oncology Summit 2024.
AbCellera will be presenting a poster: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach at Antibody Engineering & Therapeutics Europe 2024.
AbCellera will be presenting on April 16 at 6:10pm PDT at Festival of Biologics 2024.
